Gilead is adding to its flegdling oral autoimmune pipeline through a deal with a $1.3 billion upfront payment for a Phase I ...

A proposed outbound investment rule released by the U.S. Treasury Department Thursday would leave U.S. drugmakers free to ...

China’s proposed controls on specific biotechnology exports are unlikely, in themselves, to disrupt the trajectory of ...

KRAS drives most pancreatic ductal adenocarcinomas, but KRAS status alone does not reveal which nutrients a tumor relies on ...

China’s new rules for investigator-initiated trials have sharply curtailed approvals since taking effect in May, according to investigators running ...

One combined protocol can de-risk FDA acceptance of foreign data, capture the U.S. safety and PK evidence regulators want, ...

FDA’s accelerated approval of GSK’s Jemperli gives some patients with locally advanced rectal cancer a treatment that could ...

China’s out-licensing is moving beyond me-too and me-better therapies, with a growing share of deals centering on assets in the running to be first ...

• China regulation and export risk — Order 818 has sharply narrowed the IIT pathway and a proposed export-control regime ...

The Roche-Hansoh collaboration announced Monday is part of the Chinese pharma’s strategy to move beyond asset licensing to co ...

An emerging blood biomarker raises a question worth drug developers’ attention: are conventional measures of disease burden ...

For pure gene silencing, siRNA offers better durability, deeper knockdown and cleaner safety, while ASOs still matter ...